The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- RaQualia Wins Use-Patent Allowance for EP4 Antagonist in US
September 22, 2014
- Bayer’s Japan Open Innovation Center Now Up and Running
September 22, 2014
- Sadao Furuichi to Double as Heads of Kracie Pharma, Kracie Pharmaceutical
September 22, 2014
- Huya Bioscience International Opens Tokyo Office
September 19, 2014
- MTPC Generic Arm Seeks to Quickly Broaden Product Lineup, New Alliance a Possibility: Pres.
September 18, 2014
- Takeda to Reshuffle Global Structure in April
September 18, 2014
- Toray Partners with German Firm on Sales of Hemoperfusion Device in Europe
September 18, 2014
- Allergan, Shionogi Tie Up for Sales of Eyelash Hypotrichosis Agent
September 18, 2014
- Bayer Paid 10.1 Billion Yen to Healthcare Professionals in 2013
September 18, 2014
- Bristol-Myers’ 2013 Payments to Health Professionals Total 4.9 Billion Yen
September 18, 2014
- Eisai Inks Two Joint Research Deals for Novel Antimalarial Agents
September 18, 2014
- Kaketsuken Wins Grants for Dengue Vaccine Program from GHIT Fund
September 18, 2014
- Eli Lilly, AstraZeneca to Codevelop BACE Inhibitor for AD Treatment
September 18, 2014
- Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal
September 17, 2014
- Novartis Files Jakavi for Polycythemia Vera in Japan
September 17, 2014
- Nippon Shinyaku to Gear Up R&D, Commercialization of Nucleic Acid Products
September 17, 2014
- Takeda Picks Teva’s Gerard Greco as Global Quality Officer
September 17, 2014
- Sanofi Taps Call Center to Prevent Patient Dropouts from Insulin Therapy
September 16, 2014
- Pharmacy Chains Hurrying to Reach Price Settlements with Wholesalers ahead of Sept.-End Deadline
September 16, 2014
- Novartis Pharma Paid 22.9 Billion Yen to Healthcare Professionals in 2013
September 16, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…